Artificial intelligence in drug development: present status and future prospects

[Display omitted] •Advances in artificial intelligence (AI) are modernising several aspects of our lives.•The pharma industry is facing challenges to overcome the high attrition rates in drug development.•The pharma industry is collaborating with AI industries to overcome challenges.•AI will improve...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2019-03, Vol.24 (3), p.773-780
Main Authors: Mak, Kit-Kay, Pichika, Mallikarjuna Rao
Format: Article
Language:English
Subjects:
Artificial Intelligence
Drug Discovery
Drug Industry
Humans
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Advances in artificial intelligence (AI) are modernising several aspects of our lives.•The pharma industry is facing challenges to overcome the high attrition rates in drug development.•The pharma industry is collaborating with AI industries to overcome challenges.•AI will improve the efficiency of the drug development process. Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power coupled with advancements in AI technology could be utilised to revolutionise the drug development process. At present, the pharmaceutical industry is facing challenges in sustaining their drug development programmes because of increased R&D costs and reduced efficiency. In this review, we discuss the major causes of attrition rates in new drug approvals, the possible ways that AI can improve the efficiency of the drug development process and collaboration of pharmaceutical industry giants with AI-powered drug discovery firms.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2018.11.014